Elaine Urbina
Concepts (451)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Vascular Stiffness | 52 | 2025 | 479 | 12.530 |
Why?
| Hypertension | 65 | 2025 | 1236 | 12.490 |
Why?
| Cardiovascular Diseases | 77 | 2024 | 2013 | 9.380 |
Why?
| Blood Pressure | 71 | 2025 | 1743 | 9.300 |
Why?
| Diabetes Mellitus, Type 2 | 51 | 2025 | 2421 | 6.290 |
Why?
| Carotid Intima-Media Thickness | 25 | 2024 | 90 | 5.990 |
Why?
| Pulse Wave Analysis | 37 | 2025 | 252 | 4.940 |
Why?
| Blood Pressure Monitoring, Ambulatory | 17 | 2025 | 84 | 4.290 |
Why?
| Adolescent | 168 | 2025 | 20197 | 3.740 |
Why?
| Carotid Arteries | 14 | 2021 | 207 | 3.580 |
Why?
| Blood Pressure Determination | 19 | 2025 | 150 | 3.450 |
Why?
| Obesity | 38 | 2025 | 2844 | 3.440 |
Why?
| Hypertrophy, Left Ventricular | 13 | 2022 | 127 | 3.390 |
Why?
| Atherosclerosis | 15 | 2024 | 392 | 3.340 |
Why?
| Risk Factors | 101 | 2025 | 9792 | 3.040 |
Why?
| Pediatric Obesity | 19 | 2025 | 568 | 2.980 |
Why?
| Diabetes Mellitus, Type 1 | 35 | 2025 | 3601 | 2.930 |
Why?
| Child | 127 | 2025 | 20824 | 2.580 |
Why?
| Young Adult | 91 | 2025 | 12286 | 2.480 |
Why?
| Diabetic Angiopathies | 10 | 2025 | 263 | 2.150 |
Why?
| Body Mass Index | 39 | 2024 | 2244 | 2.120 |
Why?
| Risk Assessment | 23 | 2023 | 3286 | 1.930 |
Why?
| Echocardiography | 17 | 2025 | 634 | 1.920 |
Why?
| Dyslipidemias | 9 | 2024 | 176 | 1.900 |
Why?
| Heart Rate | 14 | 2022 | 807 | 1.830 |
Why?
| Male | 153 | 2025 | 63146 | 1.820 |
Why?
| Cross-Sectional Studies | 43 | 2025 | 5032 | 1.790 |
Why?
| Humans | 216 | 2025 | 128896 | 1.790 |
Why?
| Female | 157 | 2025 | 68162 | 1.750 |
Why?
| Autonomic Nervous System Diseases | 4 | 2022 | 35 | 1.740 |
Why?
| American Heart Association | 17 | 2023 | 311 | 1.560 |
Why?
| Heart Ventricles | 7 | 2019 | 778 | 1.450 |
Why?
| Prevalence | 26 | 2025 | 2540 | 1.410 |
Why?
| Ventricular Function, Left | 8 | 2022 | 526 | 1.380 |
Why?
| Adult | 81 | 2025 | 35361 | 1.290 |
Why?
| United States | 55 | 2024 | 13975 | 1.290 |
Why?
| Carotid Artery, Common | 7 | 2021 | 37 | 1.290 |
Why?
| Obesity, Morbid | 6 | 2020 | 241 | 1.290 |
Why?
| Lipoproteins | 6 | 2023 | 170 | 1.250 |
Why?
| Brachial Artery | 10 | 2024 | 205 | 1.240 |
Why?
| Practice Guidelines as Topic | 12 | 2021 | 1523 | 1.160 |
Why?
| Cholesterol, LDL | 14 | 2024 | 360 | 1.130 |
Why?
| Adiposity | 5 | 2021 | 505 | 1.100 |
Why?
| Cholesterol | 11 | 2024 | 399 | 1.090 |
Why?
| Ventricular Dysfunction, Left | 5 | 2021 | 387 | 1.080 |
Why?
| Blood Glucose | 9 | 2020 | 2086 | 1.080 |
Why?
| Age Factors | 20 | 2020 | 3133 | 1.010 |
Why?
| Triglycerides | 12 | 2024 | 519 | 1.010 |
Why?
| Lipids | 8 | 2024 | 614 | 0.990 |
Why?
| Metabolic Syndrome | 7 | 2019 | 339 | 0.990 |
Why?
| Masked Hypertension | 2 | 2022 | 3 | 0.970 |
Why?
| Sodium, Dietary | 2 | 2023 | 40 | 0.960 |
Why?
| Cholesterol, HDL | 8 | 2024 | 203 | 0.940 |
Why?
| Arteries | 4 | 2023 | 268 | 0.850 |
Why?
| Carotid Artery Diseases | 5 | 2017 | 64 | 0.850 |
Why?
| Tunica Intima | 8 | 2011 | 86 | 0.850 |
Why?
| Infectious Disease Transmission, Vertical | 1 | 2025 | 166 | 0.840 |
Why?
| White Coat Hypertension | 2 | 2025 | 6 | 0.830 |
Why?
| Pediatrics | 3 | 2021 | 1060 | 0.820 |
Why?
| Diabetic Neuropathies | 4 | 2023 | 87 | 0.820 |
Why?
| Asymptomatic Diseases | 3 | 2020 | 83 | 0.810 |
Why?
| September 11 Terrorist Attacks | 3 | 2017 | 30 | 0.810 |
Why?
| Prehypertension | 2 | 2013 | 27 | 0.780 |
Why?
| Tunica Media | 3 | 2011 | 38 | 0.780 |
Why?
| Atrial Fibrillation | 3 | 2023 | 370 | 0.780 |
Why?
| Academies and Institutes | 2 | 2021 | 47 | 0.780 |
Why?
| Mass Screening | 5 | 2019 | 1121 | 0.770 |
Why?
| Systole | 9 | 2024 | 190 | 0.760 |
Why?
| Vascular Resistance | 7 | 2014 | 373 | 0.750 |
Why?
| Autonomic Nervous System | 4 | 2019 | 75 | 0.740 |
Why?
| Biomedical Research | 4 | 2019 | 654 | 0.740 |
Why?
| Muscular Dystrophy, Duchenne | 3 | 2021 | 94 | 0.740 |
Why?
| Cardiomyopathies | 2 | 2022 | 333 | 0.730 |
Why?
| Follow-Up Studies | 16 | 2021 | 4917 | 0.730 |
Why?
| Vasodilation | 4 | 2017 | 480 | 0.720 |
Why?
| Adolescent Health | 1 | 2021 | 39 | 0.710 |
Why?
| Ohio | 9 | 2016 | 152 | 0.710 |
Why?
| Exercise | 5 | 2019 | 1923 | 0.700 |
Why?
| Essential Hypertension | 2 | 2023 | 5 | 0.700 |
Why?
| Diet, Mediterranean | 1 | 2020 | 27 | 0.680 |
Why?
| Nervous System Diseases | 1 | 2023 | 260 | 0.680 |
Why?
| Arteriosclerosis | 3 | 2013 | 86 | 0.680 |
Why?
| Endothelium, Vascular | 7 | 2018 | 917 | 0.670 |
Why?
| Insulin Resistance | 6 | 2022 | 1163 | 0.670 |
Why?
| Longitudinal Studies | 18 | 2024 | 2668 | 0.670 |
Why?
| Preventive Medicine | 1 | 2020 | 40 | 0.660 |
Why?
| Life Style | 4 | 2021 | 459 | 0.620 |
Why?
| Arrhythmias, Cardiac | 2 | 2022 | 312 | 0.590 |
Why?
| Program Development | 1 | 2020 | 360 | 0.570 |
Why?
| Predictive Value of Tests | 10 | 2024 | 1967 | 0.570 |
Why?
| Environmental Exposure | 5 | 2021 | 479 | 0.570 |
Why?
| Case-Control Studies | 12 | 2021 | 3334 | 0.560 |
Why?
| Sex Factors | 14 | 2019 | 1947 | 0.560 |
Why?
| Cardiology | 1 | 2020 | 281 | 0.550 |
Why?
| Accelerometry | 1 | 2017 | 89 | 0.540 |
Why?
| Prospective Studies | 18 | 2024 | 7060 | 0.530 |
Why?
| Elasticity | 4 | 2011 | 202 | 0.520 |
Why?
| Advisory Committees | 2 | 2016 | 231 | 0.510 |
Why?
| Particle Size | 1 | 2017 | 351 | 0.510 |
Why?
| Environmental Pollutants | 2 | 2019 | 142 | 0.510 |
Why?
| Self Report | 2 | 2020 | 796 | 0.500 |
Why?
| Blood Pressure Monitors | 1 | 2015 | 3 | 0.500 |
Why?
| Incidence | 13 | 2024 | 2634 | 0.500 |
Why?
| Prediabetic State | 2 | 2016 | 242 | 0.500 |
Why?
| Anticholesteremic Agents | 3 | 2014 | 145 | 0.490 |
Why?
| Linear Models | 9 | 2021 | 817 | 0.490 |
Why?
| Cohort Studies | 19 | 2024 | 5394 | 0.480 |
Why?
| Overweight | 6 | 2024 | 522 | 0.480 |
Why?
| DNA Methylation | 2 | 2019 | 600 | 0.470 |
Why?
| Polycystic Ovary Syndrome | 1 | 2017 | 165 | 0.460 |
Why?
| Disease Management | 2 | 2019 | 594 | 0.460 |
Why?
| Epigenesis, Genetic | 1 | 2019 | 613 | 0.450 |
Why?
| Health Planning Guidelines | 1 | 2013 | 25 | 0.440 |
Why?
| Multivariate Analysis | 6 | 2021 | 1504 | 0.440 |
Why?
| Vasculitis | 1 | 2014 | 68 | 0.440 |
Why?
| Vascular Remodeling | 1 | 2015 | 186 | 0.440 |
Why?
| Microvessels | 1 | 2014 | 79 | 0.440 |
Why?
| Child, Preschool | 23 | 2024 | 10457 | 0.430 |
Why?
| Peripheral Vascular Diseases | 1 | 2014 | 104 | 0.430 |
Why?
| Fibrosis | 2 | 2021 | 518 | 0.430 |
Why?
| Heart Diseases | 3 | 2022 | 356 | 0.420 |
Why?
| Vascular Diseases | 4 | 2020 | 241 | 0.420 |
Why?
| Observational Studies as Topic | 1 | 2013 | 108 | 0.420 |
Why?
| Diastole | 7 | 2022 | 151 | 0.410 |
Why?
| Hyperlipoproteinemia Type II | 4 | 2021 | 34 | 0.410 |
Why?
| Phthalic Acids | 1 | 2013 | 44 | 0.410 |
Why?
| Prognosis | 8 | 2021 | 3787 | 0.410 |
Why?
| Stroke Volume | 4 | 2022 | 587 | 0.370 |
Why?
| Tuberculosis | 2 | 2024 | 271 | 0.360 |
Why?
| Air Pollutants | 3 | 2021 | 321 | 0.360 |
Why?
| Carotid Artery, Internal | 1 | 2011 | 41 | 0.360 |
Why?
| Body Weight | 6 | 2021 | 931 | 0.350 |
Why?
| Myocardium | 2 | 2021 | 981 | 0.350 |
Why?
| Patient Compliance | 3 | 2024 | 563 | 0.350 |
Why?
| HIV Infections | 2 | 2025 | 2696 | 0.350 |
Why?
| Inflammation | 5 | 2021 | 2694 | 0.340 |
Why?
| Adiponectin | 1 | 2012 | 232 | 0.340 |
Why?
| Finland | 7 | 2024 | 91 | 0.330 |
Why?
| Bariatric Surgery | 3 | 2018 | 190 | 0.330 |
Why?
| Blood Flow Velocity | 5 | 2014 | 413 | 0.330 |
Why?
| Disease Progression | 7 | 2021 | 2603 | 0.330 |
Why?
| Exercise Tolerance | 2 | 2022 | 266 | 0.320 |
Why?
| Biomarkers | 14 | 2025 | 3874 | 0.310 |
Why?
| Early Diagnosis | 2 | 2024 | 232 | 0.310 |
Why?
| Heart Failure | 2 | 2022 | 2142 | 0.310 |
Why?
| Carotid Stenosis | 1 | 2009 | 85 | 0.310 |
Why?
| Pulsatile Flow | 4 | 2014 | 60 | 0.290 |
Why?
| Air Pollution | 3 | 2021 | 225 | 0.290 |
Why?
| Randomized Controlled Trials as Topic | 1 | 2013 | 1366 | 0.290 |
Why?
| Albuminuria | 2 | 2025 | 180 | 0.290 |
Why?
| Sulfonamides | 2 | 2022 | 494 | 0.280 |
Why?
| Image Interpretation, Computer-Assisted | 1 | 2009 | 253 | 0.280 |
Why?
| Heart | 2 | 2023 | 650 | 0.280 |
Why?
| Turner Syndrome | 2 | 2020 | 51 | 0.280 |
Why?
| Ultrasonography | 8 | 2021 | 727 | 0.280 |
Why?
| Executive Function | 2 | 2024 | 420 | 0.280 |
Why?
| Lipoproteins, HDL | 3 | 2021 | 85 | 0.270 |
Why?
| Bone Density | 2 | 2021 | 470 | 0.270 |
Why?
| Diagnostic Imaging | 1 | 2009 | 327 | 0.270 |
Why?
| Fluorocarbons | 2 | 2019 | 109 | 0.270 |
Why?
| Australia | 6 | 2024 | 247 | 0.260 |
Why?
| Coronary Artery Disease | 3 | 2019 | 695 | 0.260 |
Why?
| Health Promotion | 3 | 2019 | 712 | 0.260 |
Why?
| Time Factors | 6 | 2020 | 6568 | 0.260 |
Why?
| Aortic Diseases | 2 | 2017 | 112 | 0.250 |
Why?
| Comorbidity | 4 | 2019 | 1542 | 0.250 |
Why?
| Age Distribution | 4 | 2021 | 376 | 0.240 |
Why?
| Renin-Angiotensin System | 1 | 2025 | 80 | 0.230 |
Why?
| Anthropometry | 3 | 2019 | 205 | 0.230 |
Why?
| Age of Onset | 4 | 2021 | 494 | 0.230 |
Why?
| Lipoprotein(a) | 2 | 2022 | 67 | 0.230 |
Why?
| Diabetes Mellitus | 3 | 2018 | 991 | 0.230 |
Why?
| Aorta | 2 | 2017 | 410 | 0.220 |
Why?
| Smoking | 4 | 2024 | 1501 | 0.220 |
Why?
| Latent Tuberculosis | 1 | 2024 | 66 | 0.210 |
Why?
| Femoral Artery | 3 | 2014 | 176 | 0.210 |
Why?
| Magnetic Resonance Imaging | 1 | 2014 | 3348 | 0.210 |
Why?
| Research Design | 2 | 2019 | 1038 | 0.200 |
Why?
| Hypoglycemic Agents | 3 | 2020 | 1206 | 0.200 |
Why?
| Vehicle Emissions | 2 | 2021 | 55 | 0.200 |
Why?
| Antihypertensive Agents | 3 | 2024 | 487 | 0.200 |
Why?
| National Heart, Lung, and Blood Institute (U.S.) | 2 | 2021 | 102 | 0.200 |
Why?
| Pilot Projects | 4 | 2022 | 1545 | 0.200 |
Why?
| Heart Arrest, Induced | 1 | 2002 | 31 | 0.190 |
Why?
| Fontan Procedure | 2 | 2021 | 169 | 0.190 |
Why?
| Albumins | 1 | 2022 | 102 | 0.190 |
Why?
| Waist Circumference | 2 | 2019 | 137 | 0.190 |
Why?
| Transposition of Great Vessels | 1 | 2002 | 34 | 0.190 |
Why?
| Sphygmomanometers | 3 | 2012 | 9 | 0.190 |
Why?
| Triage | 1 | 2024 | 211 | 0.190 |
Why?
| Acute-Phase Proteins | 1 | 2021 | 67 | 0.190 |
Why?
| Ventricular Remodeling | 2 | 2021 | 255 | 0.190 |
Why?
| Insulin | 3 | 2020 | 2311 | 0.190 |
Why?
| Women's Health | 3 | 2011 | 361 | 0.180 |
Why?
| Allostasis | 1 | 2021 | 16 | 0.180 |
Why?
| Interdisciplinary Research | 1 | 2021 | 26 | 0.180 |
Why?
| Myocarditis | 1 | 2022 | 101 | 0.180 |
Why?
| Attention | 1 | 2024 | 434 | 0.180 |
Why?
| Sodium | 1 | 2022 | 203 | 0.180 |
Why?
| Atrial Function, Left | 1 | 2020 | 7 | 0.180 |
Why?
| Birth Weight | 1 | 2024 | 493 | 0.180 |
Why?
| Parity | 1 | 2021 | 120 | 0.180 |
Why?
| Forecasting | 2 | 2020 | 363 | 0.180 |
Why?
| Quantitative Trait, Heritable | 1 | 2021 | 119 | 0.170 |
Why?
| Sensitivity and Specificity | 2 | 2024 | 1840 | 0.170 |
Why?
| Sex Distribution | 2 | 2021 | 357 | 0.170 |
Why?
| Precision Medicine | 1 | 2024 | 385 | 0.170 |
Why?
| Middle Aged | 16 | 2024 | 30977 | 0.170 |
Why?
| Creatinine | 1 | 2022 | 485 | 0.170 |
Why?
| Epoprostenol | 1 | 2021 | 135 | 0.170 |
Why?
| Pyrimidines | 2 | 2022 | 444 | 0.170 |
Why?
| Paternal Exposure | 1 | 2019 | 1 | 0.170 |
Why?
| Motivation | 1 | 2024 | 541 | 0.170 |
Why?
| Cognition | 2 | 2024 | 1093 | 0.170 |
Why?
| Absorptiometry, Photon | 3 | 2021 | 249 | 0.170 |
Why?
| Phosphodiesterase 5 Inhibitors | 1 | 2019 | 37 | 0.160 |
Why?
| Diabetes Complications | 4 | 2023 | 227 | 0.160 |
Why?
| Regional Blood Flow | 2 | 2014 | 462 | 0.160 |
Why?
| Aging | 2 | 2021 | 1767 | 0.160 |
Why?
| Colorado | 5 | 2015 | 4443 | 0.160 |
Why?
| National Institute of Child Health and Human Development (U.S.) | 1 | 2019 | 9 | 0.160 |
Why?
| Preconception Care | 1 | 2019 | 39 | 0.160 |
Why?
| Smokers | 1 | 2020 | 135 | 0.160 |
Why?
| Sugars | 1 | 2019 | 35 | 0.160 |
Why?
| Cell Adhesion Molecules | 1 | 2020 | 177 | 0.160 |
Why?
| Histone Code | 1 | 2019 | 31 | 0.160 |
Why?
| Dimensional Measurement Accuracy | 1 | 2018 | 13 | 0.160 |
Why?
| Judaism | 1 | 2018 | 2 | 0.160 |
Why?
| Compression Bandages | 1 | 2018 | 6 | 0.160 |
Why?
| Fasting | 1 | 2020 | 265 | 0.150 |
Why?
| Dietary Carbohydrates | 1 | 2019 | 151 | 0.150 |
Why?
| Ischemic Preconditioning | 1 | 2018 | 40 | 0.150 |
Why?
| Retrospective Studies | 10 | 2024 | 14546 | 0.150 |
Why?
| Preventive Health Services | 2 | 2017 | 143 | 0.150 |
Why?
| Cognitive Dysfunction | 2 | 2023 | 328 | 0.150 |
Why?
| Maternal Exposure | 1 | 2019 | 173 | 0.140 |
Why?
| ROC Curve | 1 | 2019 | 500 | 0.140 |
Why?
| Sleep Apnea, Obstructive | 1 | 2021 | 238 | 0.140 |
Why?
| Nutrition Surveys | 2 | 2024 | 259 | 0.140 |
Why?
| Bone and Bones | 1 | 2020 | 297 | 0.140 |
Why?
| Guidelines as Topic | 1 | 2019 | 259 | 0.140 |
Why?
| Diethylhexyl Phthalate | 1 | 2017 | 15 | 0.140 |
Why?
| Genetic Predisposition to Disease | 3 | 2021 | 2270 | 0.130 |
Why?
| Proprotein Convertase 9 | 1 | 2017 | 66 | 0.130 |
Why?
| Morbidity | 2 | 2014 | 301 | 0.130 |
Why?
| Myocardial Infarction | 1 | 2024 | 1031 | 0.130 |
Why?
| Hypolipidemic Agents | 2 | 2007 | 91 | 0.130 |
Why?
| Benzhydryl Compounds | 1 | 2017 | 65 | 0.130 |
Why?
| Body Size | 1 | 2017 | 102 | 0.130 |
Why?
| Population Surveillance | 1 | 2019 | 428 | 0.130 |
Why?
| Risk | 1 | 2019 | 866 | 0.130 |
Why?
| Cardiac Surgical Procedures | 1 | 2002 | 501 | 0.130 |
Why?
| Reference Values | 4 | 2021 | 791 | 0.130 |
Why?
| Phenols | 1 | 2017 | 94 | 0.130 |
Why?
| Adolescent Behavior | 3 | 2020 | 498 | 0.130 |
Why?
| Cytokines | 2 | 2021 | 1995 | 0.130 |
Why?
| School Health Services | 1 | 2019 | 233 | 0.130 |
Why?
| Consensus | 1 | 2019 | 644 | 0.130 |
Why?
| Smoking Cessation | 1 | 2020 | 409 | 0.130 |
Why?
| Memory, Short-Term | 1 | 2018 | 255 | 0.120 |
Why?
| MicroRNAs | 2 | 2019 | 668 | 0.120 |
Why?
| Schools | 1 | 2019 | 441 | 0.120 |
Why?
| Diet Therapy | 1 | 2015 | 37 | 0.120 |
Why?
| Referral and Consultation | 1 | 2020 | 727 | 0.120 |
Why?
| Sleep Wake Disorders | 1 | 2018 | 246 | 0.120 |
Why?
| Ankle Brachial Index | 1 | 2015 | 37 | 0.120 |
Why?
| Chemical Industry | 1 | 2014 | 10 | 0.120 |
Why?
| Petroleum | 1 | 2014 | 7 | 0.120 |
Why?
| Infant, Newborn | 4 | 2024 | 5704 | 0.120 |
Why?
| Health Behavior | 2 | 2020 | 732 | 0.120 |
Why?
| Polycyclic Aromatic Hydrocarbons | 1 | 2014 | 26 | 0.120 |
Why?
| Tachycardia | 1 | 2014 | 54 | 0.120 |
Why?
| Cardiac Output | 1 | 2015 | 157 | 0.120 |
Why?
| Chi-Square Distribution | 1 | 2015 | 513 | 0.120 |
Why?
| Arm | 2 | 2018 | 107 | 0.120 |
Why?
| Electrocardiography, Ambulatory | 1 | 2014 | 58 | 0.120 |
Why?
| Laser-Doppler Flowmetry | 1 | 2014 | 34 | 0.110 |
Why?
| Heart Defects, Congenital | 1 | 2021 | 752 | 0.110 |
Why?
| Forearm | 1 | 2014 | 118 | 0.110 |
Why?
| Diet | 1 | 2021 | 1205 | 0.110 |
Why?
| Diabetic Cardiomyopathies | 1 | 2014 | 35 | 0.110 |
Why?
| Oxidative Stress | 2 | 2018 | 1220 | 0.110 |
Why?
| Magnetic Resonance Spectroscopy | 1 | 2016 | 510 | 0.110 |
Why?
| Dietary Fiber | 1 | 2014 | 51 | 0.110 |
Why?
| Surveys and Questionnaires | 3 | 2017 | 5355 | 0.110 |
Why?
| Prenatal Exposure Delayed Effects | 1 | 2019 | 544 | 0.110 |
Why?
| Hyperglycemia | 2 | 2014 | 321 | 0.100 |
Why?
| Vitamin D Deficiency | 1 | 2015 | 179 | 0.100 |
Why?
| Exercise Therapy | 2 | 2015 | 406 | 0.100 |
Why?
| Oscillometry | 2 | 2011 | 37 | 0.100 |
Why?
| Regression Analysis | 2 | 2014 | 987 | 0.100 |
Why?
| Logistic Models | 2 | 2017 | 1963 | 0.100 |
Why?
| Research | 1 | 2015 | 413 | 0.100 |
Why?
| Infant | 5 | 2019 | 8994 | 0.100 |
Why?
| Mercury | 1 | 2012 | 39 | 0.100 |
Why?
| Hot Temperature | 1 | 2014 | 362 | 0.100 |
Why?
| Vitamin D | 1 | 2015 | 384 | 0.090 |
Why?
| Aortic Coarctation | 1 | 2012 | 82 | 0.090 |
Why?
| Louisiana | 4 | 2004 | 29 | 0.090 |
Why?
| Hemodynamics | 2 | 2018 | 1095 | 0.090 |
Why?
| Rhinitis | 1 | 2012 | 152 | 0.090 |
Why?
| Pregnancy | 5 | 2024 | 6247 | 0.090 |
Why?
| Environmental Monitoring | 1 | 2013 | 330 | 0.090 |
Why?
| Postoperative Complications | 2 | 2021 | 2494 | 0.090 |
Why?
| Gastroesophageal Reflux | 1 | 2012 | 240 | 0.090 |
Why?
| Child Welfare | 1 | 2012 | 208 | 0.090 |
Why?
| Uric Acid | 2 | 2024 | 158 | 0.080 |
Why?
| Allylamine | 1 | 2009 | 8 | 0.080 |
Why?
| Motor Activity | 2 | 2014 | 666 | 0.080 |
Why?
| Reproducibility of Results | 3 | 2024 | 3042 | 0.080 |
Why?
| Manometry | 1 | 2009 | 92 | 0.080 |
Why?
| Skin | 1 | 2014 | 737 | 0.080 |
Why?
| Cluster Analysis | 1 | 2011 | 479 | 0.080 |
Why?
| Exercise Test | 1 | 2012 | 619 | 0.080 |
Why?
| Severity of Illness Index | 1 | 2017 | 2767 | 0.080 |
Why?
| Ultrasonography, Doppler | 1 | 2009 | 118 | 0.080 |
Why?
| Particulate Matter | 2 | 2021 | 249 | 0.070 |
Why?
| Statistics as Topic | 3 | 2004 | 306 | 0.070 |
Why?
| Leg | 1 | 2010 | 241 | 0.070 |
Why?
| Eating | 2 | 2021 | 366 | 0.070 |
Why?
| Combined Modality Therapy | 3 | 2020 | 1213 | 0.070 |
Why?
| Magnetic Resonance Angiography | 1 | 2009 | 237 | 0.070 |
Why?
| Health Surveys | 2 | 2020 | 485 | 0.070 |
Why?
| Neoplasms | 1 | 2021 | 2426 | 0.070 |
Why?
| Weight Loss | 2 | 2024 | 723 | 0.070 |
Why?
| C-Reactive Protein | 2 | 2019 | 394 | 0.060 |
Why?
| Fibrinogen | 2 | 2019 | 159 | 0.060 |
Why?
| Metformin | 2 | 2020 | 307 | 0.060 |
Why?
| Midwestern United States | 1 | 2024 | 41 | 0.060 |
Why?
| Adipose Tissue | 1 | 2008 | 588 | 0.060 |
Why?
| Treatment Outcome | 4 | 2019 | 10239 | 0.060 |
Why?
| Arterial Occlusive Diseases | 1 | 2004 | 79 | 0.060 |
Why?
| Bioprosthesis | 1 | 2003 | 40 | 0.050 |
Why?
| Nitric Oxide Synthase | 1 | 2004 | 238 | 0.050 |
Why?
| Mass Spectrometry | 2 | 2019 | 659 | 0.050 |
Why?
| Ventricular Outflow Obstruction | 1 | 2003 | 41 | 0.050 |
Why?
| Arterial Pressure | 1 | 2023 | 118 | 0.050 |
Why?
| Drug Therapy, Combination | 2 | 2020 | 1020 | 0.050 |
Why?
| Body Constitution | 1 | 2002 | 53 | 0.050 |
Why?
| Reward | 1 | 2024 | 238 | 0.050 |
Why?
| Renal Insufficiency, Chronic | 1 | 2008 | 561 | 0.050 |
Why?
| Heart Atria | 1 | 2022 | 126 | 0.050 |
Why?
| Heart Valve Prosthesis | 1 | 2003 | 132 | 0.050 |
Why?
| Iowa | 1 | 2021 | 28 | 0.050 |
Why?
| Ventricular Function | 1 | 2002 | 61 | 0.050 |
Why?
| Mendelian Randomization Analysis | 1 | 2021 | 50 | 0.050 |
Why?
| Gadolinium | 1 | 2021 | 77 | 0.050 |
Why?
| Venous Pressure | 1 | 2021 | 9 | 0.050 |
Why?
| Polymorphism, Genetic | 1 | 2004 | 641 | 0.050 |
Why?
| Heart Valve Prosthesis Implantation | 1 | 2003 | 198 | 0.050 |
Why?
| Pregnancy Complications | 2 | 2019 | 487 | 0.050 |
Why?
| Intra-Abdominal Fat | 1 | 2021 | 89 | 0.040 |
Why?
| Sitosterols | 1 | 2020 | 2 | 0.040 |
Why?
| Stem Cell Transplantation | 1 | 2022 | 167 | 0.040 |
Why?
| Double-Blind Method | 2 | 2019 | 1858 | 0.040 |
Why?
| United Kingdom | 1 | 2021 | 263 | 0.040 |
Why?
| Body Height | 1 | 2021 | 191 | 0.040 |
Why?
| Phytosterols | 1 | 2020 | 12 | 0.040 |
Why?
| Magnetic Resonance Imaging, Cine | 1 | 2021 | 181 | 0.040 |
Why?
| Myocardial Contraction | 1 | 2002 | 336 | 0.040 |
Why?
| Multicenter Studies as Topic | 1 | 2021 | 287 | 0.040 |
Why?
| Public Health | 1 | 2024 | 493 | 0.040 |
Why?
| Echocardiography, Doppler | 1 | 2020 | 111 | 0.040 |
Why?
| Infant Health | 1 | 2019 | 24 | 0.040 |
Why?
| Croatia | 1 | 2019 | 5 | 0.040 |
Why?
| Organ Size | 1 | 2020 | 446 | 0.040 |
Why?
| Placebo Effect | 1 | 2019 | 57 | 0.040 |
Why?
| Intersectoral Collaboration | 1 | 2019 | 61 | 0.040 |
Why?
| Natriuretic Peptide, Brain | 1 | 2019 | 101 | 0.040 |
Why?
| Infertility | 1 | 2019 | 50 | 0.040 |
Why?
| Electrocardiography | 1 | 2022 | 602 | 0.040 |
Why?
| Research Support as Topic | 1 | 2019 | 113 | 0.040 |
Why?
| Education | 1 | 2019 | 98 | 0.040 |
Why?
| Contrast Media | 1 | 2021 | 387 | 0.040 |
Why?
| Risk Reduction Behavior | 1 | 2020 | 212 | 0.040 |
Why?
| Athletes | 1 | 2022 | 407 | 0.040 |
Why?
| Alabama | 1 | 2018 | 37 | 0.040 |
Why?
| Diabetic Retinopathy | 1 | 2020 | 170 | 0.040 |
Why?
| Carbon | 1 | 2019 | 205 | 0.040 |
Why?
| Child Health | 1 | 2019 | 145 | 0.040 |
Why?
| Child Behavior | 1 | 2020 | 235 | 0.040 |
Why?
| Transition to Adult Care | 1 | 2019 | 74 | 0.040 |
Why?
| Drug Administration Schedule | 1 | 2019 | 760 | 0.040 |
Why?
| New York City | 1 | 2017 | 81 | 0.040 |
Why?
| Congresses as Topic | 1 | 2019 | 217 | 0.040 |
Why?
| Guideline Adherence | 2 | 2012 | 526 | 0.030 |
Why?
| Oxygen | 1 | 2022 | 912 | 0.030 |
Why?
| Animals | 1 | 2019 | 34628 | 0.030 |
Why?
| Radial Artery | 1 | 2017 | 68 | 0.030 |
Why?
| Diabetic Nephropathies | 1 | 2020 | 272 | 0.030 |
Why?
| Dilatation, Pathologic | 1 | 2016 | 61 | 0.030 |
Why?
| Body Surface Area | 1 | 2016 | 34 | 0.030 |
Why?
| Europe | 1 | 2017 | 366 | 0.030 |
Why?
| Oxygen Consumption | 1 | 2019 | 676 | 0.030 |
Why?
| Thrombosis | 1 | 2019 | 331 | 0.030 |
Why?
| Patient Education as Topic | 2 | 2011 | 734 | 0.030 |
Why?
| Terminology as Topic | 1 | 2017 | 204 | 0.030 |
Why?
| Interleukin-6 | 1 | 2019 | 715 | 0.030 |
Why?
| Videoconferencing | 1 | 2015 | 62 | 0.030 |
Why?
| Fractures, Bone | 1 | 2020 | 416 | 0.030 |
Why?
| Patient Selection | 1 | 2018 | 671 | 0.030 |
Why?
| Proportional Hazards Models | 1 | 2017 | 1221 | 0.030 |
Why?
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 2 | 2009 | 421 | 0.030 |
Why?
| Socioeconomic Factors | 1 | 2018 | 1192 | 0.030 |
Why?
| Nutrition Policy | 1 | 2014 | 56 | 0.030 |
Why?
| Aged | 2 | 2024 | 22035 | 0.030 |
Why?
| Blood Cell Count | 1 | 2012 | 54 | 0.030 |
Why?
| Internationality | 1 | 2013 | 148 | 0.030 |
Why?
| Databases, Factual | 1 | 2018 | 1289 | 0.030 |
Why?
| Liver | 1 | 2021 | 1832 | 0.020 |
Why?
| Dust | 1 | 2012 | 100 | 0.020 |
Why?
| Clinical Trials as Topic | 2 | 2007 | 1002 | 0.020 |
Why?
| Analysis of Variance | 1 | 2015 | 1283 | 0.020 |
Why?
| Spirometry | 1 | 2012 | 252 | 0.020 |
Why?
| Headache | 1 | 2012 | 138 | 0.020 |
Why?
| Sex Characteristics | 1 | 2017 | 722 | 0.020 |
Why?
| Gene Expression Profiling | 1 | 2018 | 1694 | 0.020 |
Why?
| Chronic Disease | 1 | 2017 | 1715 | 0.020 |
Why?
| Health Status | 1 | 2016 | 750 | 0.020 |
Why?
| Inservice Training | 1 | 2012 | 113 | 0.020 |
Why?
| Observer Variation | 1 | 2012 | 321 | 0.020 |
Why?
| Circadian Rhythm | 1 | 2014 | 401 | 0.020 |
Why?
| Sound | 1 | 2011 | 67 | 0.020 |
Why?
| Eosinophils | 1 | 2012 | 324 | 0.020 |
Why?
| Colesevelam Hydrochloride | 1 | 2009 | 8 | 0.020 |
Why?
| Electronic Health Records | 1 | 2017 | 966 | 0.020 |
Why?
| Aged, 80 and over | 1 | 2021 | 7050 | 0.020 |
Why?
| Registries | 1 | 2017 | 1916 | 0.020 |
Why?
| Social Class | 1 | 2011 | 256 | 0.020 |
Why?
| Cost-Benefit Analysis | 1 | 2011 | 615 | 0.020 |
Why?
| Hyperlipoproteinemias | 1 | 2007 | 7 | 0.020 |
Why?
| Cholesterol, Dietary | 1 | 2007 | 18 | 0.020 |
Why?
| Contraindications | 1 | 2007 | 90 | 0.020 |
Why?
| Drug-Related Side Effects and Adverse Reactions | 1 | 2009 | 259 | 0.020 |
Why?
| Diet, Fat-Restricted | 1 | 2007 | 79 | 0.020 |
Why?
| HIV Protease Inhibitors | 1 | 2007 | 63 | 0.020 |
Why?
| Phytotherapy | 1 | 2007 | 76 | 0.020 |
Why?
| Dose-Response Relationship, Drug | 1 | 2009 | 1968 | 0.020 |
Why?
| Dietary Fats | 1 | 2007 | 302 | 0.010 |
Why?
| Equipment Design | 1 | 2006 | 522 | 0.010 |
Why?
| Glomerular Filtration Rate | 1 | 2008 | 684 | 0.010 |
Why?
| Los Angeles | 1 | 2003 | 62 | 0.010 |
Why?
| Nitric Oxide Synthase Type III | 1 | 2004 | 204 | 0.010 |
Why?
| Genetic Markers | 1 | 2004 | 335 | 0.010 |
Why?
| Gene Frequency | 1 | 2004 | 503 | 0.010 |
Why?
| Pulmonary Valve | 1 | 2003 | 99 | 0.010 |
Why?
| Alleles | 1 | 2004 | 847 | 0.010 |
Why?
| Aortic Valve | 1 | 2003 | 425 | 0.010 |
Why?
| Asthma | 1 | 2012 | 2258 | 0.010 |
Why?
| Genotype | 1 | 2004 | 1834 | 0.010 |
Why?
| Pulmonary Artery | 1 | 2003 | 1091 | 0.010 |
Why?
|
|
Urbina's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|